Catalent to Expand its Argentinian Site

August 6, 2020
BioPharm International Editors

The expanded facility will feature two new 40-L and 300-L manufacturing vessels, a capsule filling line, and six drying tunnels that will add more than 10 million doses per annum to the site.

Catalent announced on August 4, 2020 that it is expanding its Argentinian site in Loma Hermosa, Buenos Aires, Argentina, to accommodate more than 11,000 ft2 of production space to handle cytotoxic and highly active products for prescription softgel manufacturing.

The expanded facility will feature two new 40-L and 300-L manufacturing vessels, a capsule filling line, and six drying tunnels that will add more than 10 million doses per annum to the site, a company press release said. The facility is expected to be completed in December 2021.

“This investment will allow the site to grow and handle a wider range of projects, reacting to the increased demands of the industry for high potency treatments in areas such as oncology,” commented Sergio Alter, vice president and general manager, Softgel Technologies, Latin America, in the press release. “Not only will this increase the capacity of the site, but the design of the new facility will see it meet the highest standards of environmental and energy efficiency.”

Source: Catalent